• 

• CAS 247062-33-5 Abaloparatide

  Description Abaloparatide is a parathyroid hormone receptor 1 (PTHR1) analog and a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide is used to treat osteoporosis.

  Uses Abaloparatide, a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis in specific patient populations. The drug is indicated for postmenopausal women who are at a high risk of fracture, which can be defined by a history of osteoporotic fracture, multiple risk factors for fracture, or those who have failed or are intolerant to other available osteoporosis therapies. In addition to its use in postmenopausal women, abaloparatide has also been approved for increasing bone density in men with osteoporosis who are at high risk for fractures. This approval extends to adult patients who have not responded effectively to or cannot tolerate other osteoporosis treatments. The drug is designed to stimulate bone formation, thereby reducing the risk of fractures associated with osteoporosis.

  
  

  Price on request

  REQUEST NOW

Product Introduction:

Product Name: Abaloparatide

Synonyms: Abaloparatide;Abaloparatide (BA058)

CAS: 247062-33-5

MF: C174H300N56O49

MW: 3960.5896